Taking Aim at HER3 in Lung Cancers Resistant to EGFR Inhibitors

Gain expert perspectives on the evolving role of HER3 in EGFR-mutated advanced NSCLC including the role of HER3-targeted therapies in the setting of EGFR TKI resistance with this educational program featuring a series of short interactive virtual presentations with downloadable slidesets and a multidisciplinary audio podcast.

Share

Program Content

Activities

Slides: ADCs in Lung Cancer Care
Antibody–Drug Conjugates in Lung Cancer Care
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2022

Expires: February 06, 2023

Slides: HER3 in Lung Cancer
Role of HER3 in Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2021

Expires: October 26, 2022

Slides: EGFR TKI Resistance
Mechanisms of Resistance to EGFR TKI Therapy in Advanced Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2021

Expires: November 18, 2022

Slides: Tx After EGFR TKI
Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 19, 2021

Expires: November 18, 2022

Activities

<i>EGFR</i>+ NSCLC: Multidisciplinary Overview
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2022

Expires: January 25, 2023

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.